| Drug General Information |
| Drug ID |
D0V8HJ
|
| Former ID |
DNCL001657
|
| Drug Name |
Fostamatinib
|
| Drug Type |
Small molecular drug
|
| Indication |
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06]
|
Phase 3 |
[1],
[2]
|
|---|
| Company |
AstraZeneca; Rigel Pharmaceuticals
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C23H26FN6O9P
|
| InChI |
InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)
|
| InChIKey |
GKDRMWXFWHEQQT-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
16775273, 23769915, 75389485, 96026027, 124360793, 125164706, 125299332, 126665637, 134338877, 135262180, 135693729, 136367938, 137245316, 141853032, 144115995, 152159558, 152344305, 160681714, 162038039, 164043535, 164160256, 170501470, 172087031, 172818901, 174006453, 174531355, 185997057, 188941735, 198973453, 206261469, 210274820, 210280453, 223366127, 223388366, 223684830, 227435155, 242060176, 246229128, 251971029, 252215442
|
| Target and Pathway |
| Target(s) |
Tyrosine-protein kinase SYK |
Target Info |
Modulator |
[3]
|
|---|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Osteoclast differentiation
|
|
Platelet activation
|
|
Natural killer cell mediated cytotoxicity
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
Tuberculosis
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesis
|
|
PANTHER Pathway
|
B cell activation
|
|
Pathway Interaction Database
|
Fc-epsilon receptor I signaling in mast cells
|
|
BCR signaling pathway
|
|
GMCSF-mediated signaling events
|
|
Atypical NF-kappaB pathway
|
|
Osteopontin-mediated events
|
|
FAS (CD95) signaling pathway
|
|
Thromboxane A2 receptor signaling
|
|
IL2-mediated signaling events
|
|
Class I PI3K signaling events
|
|
Alpha-synuclein signaling
|
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Reactome
|
GPVI-mediated activation cascade
|
|
FCGR activation
|
|
Regulation of actin dynamics for phagocytic cup formation
|
|
Role of phospholipids in phagocytosis
|
|
DAP12 signaling
|
|
Fc epsilon receptor (FCERI) signaling
|
|
Role of LAT2/NTAL/LAB on calcium mobilization
|
|
FCERI mediated MAPK activation
|
|
FCERI mediated Ca+2 mobilization
|
|
Integrin alphaIIb beta3 signaling
|
|
Interleukin-2 signaling
|
|
CLEC7A (Dectin-1) signaling
|
|
Dectin-2 family
|
|
Regulation of signaling by CBL
|
|
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
WikiPathways
|
IL-2 Signaling Pathway
|
|
IL-3 Signaling Pathway
|
|
Fc epsilon receptor (FCERI) signaling
|
|
Signaling by the B Cell Receptor (BCR)
|
|
Interleukin-2 signaling
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
DAP12 interactions
|
|
B Cell Receptor Signaling Pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Integrin alphaIIb beta3 signaling
|
|
GPVI-mediated activation cascade
|
|
Regulation of toll-like receptor signaling pathway
|
|
IL-5 Signaling Pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01197521) Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.. U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7796). |
|---|
| REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230). |
|---|
